M. Valladares-Ayerbes

Retrospective analysis of management of BRAF V600E mutated colorectal cancer in a single institution

BackgroundBRAF V600E mutation is estimated to be present in 5-20% of all new diagnosis of metastasic colorectal cancer, in which allocates a poor prognosis, with a median overall survival...

Pérez R. Buezas ;

Sempere J. Torres ;

Vicente A. Pereira ;

Ladrón A. López ;

J. Rodriguez ;

L. Limon ;

Jimenez Gallego ;

M. Valladares-Ayerbes ;

Velasco R. Pérez ;

Rodríguez P. Macías ;

Grove C. Garcia ;

Sánchez D. Martín ;

C. Torrado ;

A. Barroso ;

F. Tallafigo ;

E. Monescillo ;

06/25/2023

Results of REARRANGE trial: A randomized phase 2 study comparing different dosing approaches for regorafenib (REG) during the first cycle of treatment in patients (pts) with metastatic colorectal cancer (mCRC)

IntroductionREG is a multi-kinase inhibitor that improves overall survival vs placebo in refractory mCRC. However, REG adverse tolerability profile often limits its use on normal clinica...

T. Cano ;

F. Loupakis ;

Josep Tabernero , MD, PhD;

M. Rodriguez Garrote ;

F. Herrero Rivera ;

R. Goldberg ;

J. Bennouna ;

Fortunato Ciardiello ;

A. Falcone ;

E. Aranda ;

G. Argiles ;

N. Mulet Margalef ;